The launch of the first and only 755 nm FDA-cleared laser to treat melasma pigment
Introducing the PicoSure Pro. It’s the first and only FDA-cleared 755 nm picosecond laser on the market, designed to uniquely deliver energy in a trillionth of a second, utilising pressure instead of heat to provide safe and effective treatments for unwanted pigmentation and skin revitalisation of all skin types. It is also the first FDA-cleared laser to treat melasma, as well as other hyperpigmentation issues such as Nevus of Ota and Hori’s nevus.
With more than one million treatments performed and 100% patient satisfaction,1 PicoSure has become a popular and trusted treatment worldwide. The enhancements of the new system offer practitioners greater versatility, treating more patients a day but with even better outcomes, lightening pigment in two to three sessions. Additional enhancements include a sleek, modern design, intuitive graphic user interface and new 5mm handpiece for treating discrete lesions, lighter skin types and smaller areas.
Todd Tillemans, chief executive officer of Cynosure, comments, “As inventors of picosecond aesthetic laser technology, we are constantly challenging ourselves to continually drive innovation forward. Whether we’re developing new devices or improving upon our trusted flagship products, we’re focused on addressing the unmet needs of our practitioners to ensure the best possible outcomes for their patients and practice. From a 50% increase in energy to new handpieces and an adjustable fluence, the performance enhancements made to the PicoSure Pro device provide practitioners with more versatility than ever before, allowing them to efficiently treat more patients per day and provide better outcomes in less time.”
There is no downtime following the use of this device. Patients may experience erythema that typically resolves within a few hours, but in some cases, may linger up to 24 hours. Since each patient is unique, it is highly recommend to follow the outlined clinical guidelines to help optimise safety and efficacy before treatment.
Dr Asif Hussain, cosmetic dermatology and laser surgery specialist, comments, “I’m proud to be one of the first practitioners in the UK to use the PicoSure Pro device. The upgraded technology makes it even easier for me to effectively treat a variety of skin health and pigmentation concerns – with the added prestige of the FDA-cleared melasma indication, which impacts a significant number of my patients. With PicoSure Pro, I can achieve comparable treatment results to more aggressive lasers with less pain and no downtime, making it a true one-and-done device for a myriad of patient needs.”
Cynosure will be running an exclusive industry event around melasma and introducing the PicoSure Pro on May 25, 2022, at its International head offices in Chiswick, London. For more information about PicoSure Pro, or to register for the event, contact firstname.lastname@example.org